Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Fierce Biotech Layoff Tracker 2026: Replimune reduces staff; Astellas shutters cell therapy site

Published

on

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy

Published

on

The FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10 to 3 in favor of Replimune’s immunotherapy for advanced melanoma in combination with Bristol Myers Squibb’s Opdivo, but trial design was a major sticking point as the panel deliberated.

Continue Reading

Uncategorized

Replimune melanoma drug wins support of FDA panel

Published

on

The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.

Continue Reading

Uncategorized

Alnylam plunges as earnings deliver ‘one-two punch’

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Read More

Published

on

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Read More

Continue Reading
Advertisement

Trending